Skip to main content

Advertisement

Table 1 Baseline clinical features and demographic features by R+ group as defined at month 12

From: How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose

  R+ ≤ 100 mg (n = 38) R+  101–200 mg (n = 46) R+ > 200 mg (n = 48) P value
Age, yearsa 61.2 (13.3) 64.1 (9.8) 55.1 (11.6) 0.001
Male, n (%) 32 (84.2) 40 (87.0) 46 (95.8) 0.18
NZ European, n (%) 20 (52.6) 25 (54.3) 16 (33.3) 0.08
Duration of gout years, median (range) 15.2 (1.2–40.4) 18.9 (0.16–49.5) 15.7 (0.37–47.4) 0.49
Baseline serum urate mg/dla 6.6 (1.6) 6.6 (1.0) 7.6 (1.5) <0.001
CrCl ml/mina 65.0 (29.4) 56.7 (19.4) 65.5 (27.9) 0.19
Weight kga, mean (SD) 99.2 (21.6) 104.3 (21.4) 114.3 (20.6) 0.004
Body mass index, kg/m2a 32.2 (6.3) 35.2 (7.9) 36.6 (7.3) 0.23
Baseline allopurinol dosea 250 (103) 248 (67) 316 (123) 0.002
Baseline oxypurinol concentrations, μmol/la 87.1 (42.0) 96.9 (47.9) 90.9 (56.8) 0.66
Co-existing conditions, n (%)
 Obesityb 20 (52.6) 35 (76.1) 41 (85.4) 0.003
 Cardiovascular diseasec 12 (31.6) 21 (45.7) 18 (37.5) 0.41
 Diabetes mellitus 11 (28.9) 16 (34.8) 16 (33.3) 0.84
 Hypertension 27 (71.1) 36 (78.3) 31 (64.6) 0.34
 Hyperlipidemia 25 (65.8) 25 (54.3) 25 (52.1) 0.41
Diuretic, n (%) 12 (31.6) 22 (47.8) 18 (37.5) 0.30
  1. R+ amount of allopurinol (milligrams) above creatinine clearance-based dose, CrCL creatinine clearance
  2. aMean (SD)
  3. bObesity defined as body mass index ≥ 30 kg/m2
  4. cCVD defined as ischemic heart disease, heart failure or peripheral vascular disease